Novartis Hopes Encore Can Lead To Eye-Watering Presbyopia Success
Executive Summary
Novartis is buying a privately-held US company started by an ex-Alcon executive which is developing an eye drop aimed at curing presbyopia, a condition affecting some 80% of people over the age of 45.
You may also be interested in...
Deal Watch: Bristol And Otsuka Pursue Oncolytic Virus Therapies Via Licensing Deals
Busy stretch before Christmas holidays sees two deals around oncolytic virus therapeutics, a Middle East partnership for Orexigen’s Contrave, immuno-oncology deals involving Pfizer and ElsaLys, and Roche and ImmuNext partnering to develop drugs targeting the VISTA pathway.
Novartis Chief: Good Things Come To Those Who Wait
In the company’s third-quarter conference call, Novartis CEO Joe Jimenez admitted that generic competition to its blockbuster Gleevec will continue to drag on the company in 2017. However, he touted a pipeline of 12 potential blockbusters and restructuring efforts over the past three years as evidence that the company will be positioned for growth from 2018.
Novartis finally completes Alcon buy
Novartis has completed its acquisition of eyecare specialist Alcon, after shareholders approved the proposed takeover, worth $51.6bn in total, earlier today. Alcon's shareholders gave the acquisition the green light yesterday.